Cardiac Imaging in Carcinoid Heart Disease

Baron, Tomasz; Bergsten, Johannes; Albåge, Anders; Lundin, Lennart; Sørensen, Jens Nørkær; Öberg, Kjell; Flachskampf, Frank A.

doi:10.1016/j.jcmg.2020.12.030

Cited by 11 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3C Cardiac magnetic resonance imaging (CMRI) and cardiac CT (CCT) are useful additional modalities, used when TTE images are inadequate or in pre‐operative planning (Table 6). 32 3B At the same time, it should be noted that assessment of severity of pulmonary vein (PV) involvement with echocardiography can be difficult and misleading, and functional assessment of pulmonary regurgitation with MRI should also be measured and interpreted with care. Full cardiac CT (requiring a high‐pitch or high‐volume CT scanner) allows excellent anatomical visualisation of the pulmonary valve. In addition, it allows assessment of coronary arteries, relationship of cardiac metastases (if present) with regard to coronary arteries, and RV function assessment being mostly utilised in pre‐operative planning 33 .…”

Section: B Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease

Glasberg

Davar

Hofland

et al. 2022

J Neuroendocrinology

Self Cite

125

View full text Add to dashboard Cite

Data regarding the diagnosis, management, and follow-up of carcinoid syndrome (CS) and carcinoid heart disease (CHD) were identified by searches of the MEDLINE database using specific terms in human studies: CS; CHD; screening; epidemiology; diagnosis; treatment; prognosis. The search results were supplemented by manual searching of relevant journals, reference lists in key articles and other appropriate documents, and expert opinion. All recommendations are offered on the basis of the best available evidence, supplemented by the authors' experiences in managing CS and CHD. Each recommendation for treatment will have a level of evidence and grade of recommendation as per the GRADE system (adapted in Infectious Disease society This first ENETS guidance paper on CS aims to provide practical guidance for NEN specialists in the diagnosis and management of CS, with special emphasis on CHD.

show abstract

Section: B Diagnosismentioning

confidence: 99%

“…Be aware that, with severe TR, PV involvement degree could be underestimated and that functional assessment of PR severity either with echocardiography or MRI could be misleading 68 . 4B Assessment of valve size can be achieved using CCT 32 . 4B Assess liver/renal/coagulation tests and perform carotid Doppler.…”

Section: Therapymentioning

confidence: 99%

European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease

Glasberg

Davar

Hofland

et al. 2022

J Neuroendocrinology

Self Cite

125

View full text Add to dashboard Cite

show abstract

“…As functional parameters are known to be load dependent, severe valvular regurgitation and stenosis play a further role in worsening right ventricular function [ 20 ]. Therefore, further deterioration of cardiac function in the course of the disease is likely and evaluation of different parameters of right ventricular function and morphology is recommended [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence, one-year-incidence and predictors of carcinoid heart disease

Mattig,

Franke,

Pschowski

et al. 2023

Cardiovasc Ultrasound

View full text Add to dashboard Cite

Background Carcinoid heart disease (CHD) caused by neuroendocrine tumours (NET) is associated with an increased morbidity and mortality due to valvular dysfunction and right sided heart failure. The present study aimed to assess the prevalence and one-year-incidence of CHD in NET patients. Tumour characteristics, laboratory measurements, and echocardiographic findings were evaluated to identify predictors of CHD manifestation. Methods The study was an investigator-initiated, monocentric, prospective trial. Patients with NET without previously diagnosed CHD were included and underwent comprehensive gastroenterological and oncological diagnostics. Echocardiographic examinations were performed at baseline and after one year. Results Forty-seven NET patients were enrolled into the study, 64% of them showed clinical features of a carcinoid syndrome (CS). Three patients presented with CHD at baseline and three patients developed cardiac involvement during the follow-up period corresponding to a prevalence of 6% at baseline and an incidence of 6.8% within one year. Hydroxyindoleacetic acid (5-HIAA) was identified to predict the occurrence of CHD (OR, 1.004; 95% CI, 1.001–1.006 for increase of 5-HIAA), while chromogranin A (CgA), and Kiel antigen 67 (Ki 67%) had no predictive value. Six patients with CHD at twelve-month follow-up revealed a tendency for larger right heart diameters and increased values of myocardial performance index (MPEI) at baseline compared to NET patients. Conclusion The prevalence at baseline and one-year-incidence of CHD was 6–7%. 5-HIAA was identified as the only marker which predict the development of CHD. Graphical Abstract

show abstract

“… 20 Os achados típicos na RMC são espessamento da válvula tricúspide e/ou dos folhetos da válvula pulmonar com defeitos de coaptação. 21 Utilizando contraste de fase, é possível estimar os volumes de regurgitação e classificar o envolvimento da válvula como leve, moderado ou grave. 21 Neste paciente, a RMC mostrou um envolvimento difuso raro do VD, com fibrose na válvula tricúspide, miocárdio e no músculo papilar.…”

Section: Relato De Casounclassified

“…É essencial consultar o oncologista no momento da decisão terapêutica para avaliar o controle adequado da SC e a expectativa de vida para ponderar os riscos e os benefícios da cirurgia. 21 …”

Section: Relato De Casounclassified